Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 63 out of 100. Genetics

Topic: Risk, prevention and care in population studies

Plain-language summary

Overall, cumulative incidence was uniformly higher in NACC than in the population-based cohorts. Among APOE-e4/e4 individuals, 5-y cumulative incidence was as follows: in the 60-64-y age stratum, it ranged from 0% to 5.88% in the three population-based cohorts versus 23.06% in NACC; in the 65-69-y age stratum, from 9.42% to 10.39% versus 34.62%; and in the 70-75-y age stratum, from 18.64% to 33.33% versus 38.34%. In regression models, APOE-e4 dose and age both consistently increased risk, as did lower education, subjective memory concerns, poorer baseline cognitive performance, and family history of dementia.

What this study adds

Evidence grade: Moderate

The record lists 5,073 participants. Cumulative incidence was consistently higher in the clinic-based NACC cohort than in the population-based cohorts. Reported effect size: 5.88%; 23.06%; 9.42% to 10.39%.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Qian, J., Wolters, F. J., Beiser, A., Haan, M., Ikram, M. A., Karlawish, J., et al. (2017). APOE-related risk of mild cognitive impairment and dementia for prevention trials: An analysis of four cohorts. PLoS medicine. https://doi.org/10.1371/journal.pmed.1002254

Vancouver

Qian J, Wolters FJ, Beiser A, Haan M, Ikram MA, Karlawish J, et al. APOE-related risk of mild cognitive impairment and dementia for prevention trials: An analysis of four cohorts. PLoS medicine. 2017. doi:10.1371/journal.pmed.1002254. PMID: 28323826.

BibTeX

@article{qian2017-28323826,
  author  = {Qian, J. and Wolters, F. J. and Beiser, A. and Haan, M. and Ikram, M. A. and Karlawish, J. and Langbaum, J. B. and Neuhaus, J. M. and others},
  title   = {{APOE-related risk of mild cognitive impairment and dementia for prevention trials: An analysis of four cohorts}},
  journal = {PLoS medicine},
  year    = {2017},
  doi     = {10.1371/journal.pmed.1002254},
  pmid    = {28323826},
  url     = {https://doi.org/10.1371/journal.pmed.1002254}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Why it matters

This analysis of four cohorts found that the risk of mild cognitive impairment and dementia increased with the dose of the APOE epsilon 4 allele and with age, and was also higher with lower education, subjective memory concerns, poorer baseline cognition and family history of dementia. Cumulative incidence was consistently higher in the clinic-based NACC cohort than in the population-based cohorts.

Study details

How this study scored 63/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 3 of 4; Study design 0 of 12; Strength of evidence 3 of 5; Peer-review validation 10 of 10; How recent 2 of 5; Sample size 3 of 4; Effect reported 2 of 3; Studied in people 3 of 3; Randomized / blinded 0 of 2; Times cited 5 of 7; Citations per year 3 of 5; Impact for its field and year 4 of 6; Cited by studies here 3 of 6; Still being cited 2 of 4; Senior author's track record 3 of 4; Institution's track record 3 of 3; Multicenter collaboration 3 of 3; Indexed in PubMed 2 of 2; Free to read 2 of 2. Total 63 of 100.63 of 100 points earned37 not earned

Published in a peer-reviewed journal. Scored zero for study design and randomized / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (PLoS medicine)
Journal's citation record 3 / 4 PLoS Medicine: journal h-index 350 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 3 / 5 Rated “moderate” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 2 / 5 2017 — within 10 year(s) of the newest study here
Sample size 3 / 4 5,073 participants
Effect reported 2 / 3 Effect reported as a number, without an interval or test
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 5 / 7 Cited 168 times (OpenAlex, 2026-10-10)
Citations per year 3 / 5 15.3 citations a year over 11 year(s) since 2017
Impact for its field and year 4 / 6 Cited 11.8× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 3 / 6 Cited by 22 other studies in this library
Still being cited 2 / 4 Cited 47 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 3 / 4 Last-listed author Deborah Blacker: h-index 86 (OpenAlex, whole career)
Institution's track record 3 / 3 Harvard University: institution h-index 3,235 (OpenAlex)
Multicenter collaboration 3 / 3 OpenAlex lists 12 institution(s) in 2 countries
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 28323826)
Free to read 2 / 2 Free to read
Total 63 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 22.

Later studies that cite this one

22 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.

Related studies in Genetics from nearby years

Also tagged “biobank”

1,084 studies in the library carry the topic tag “biobank”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,084 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Genetics

See all studies in Genetics →